Arexis

Arexis receives European patent on a novel target for diabetes treatment

Wed, Jun 08, 2005 15:00 CET

The drug development company Arexis AB announced today that it has received a European patent covering the skeletal muscle specific γ3 subunit of AMPK, representing an important part of Arexis’ patent portfolio in the AMPK field. Arexis is currently developing a novel oral therapy based on a non-insulin dependent mechanism for type II diabetes, with AMPK as target.The granted patent – ‘Variants of the gamma chain of AMPK, DNA sequences encoding the same, and uses thereof’ – covers the skeletal muscle specific γ3 subunit of AMPK (Adenosine 5´monophosphate-activated protein kinase). It will

Rein Seensalu joins Arexis as Vice President Clinical Science and Development

Mon, May 30, 2005 08:00 CET

GOTHENBURG, SWEDEN – 30 May 2005 – the drug development company Arexis AB announced today that Rein Seensalu has joined the company, taking charge of the clinical development with the position as Vice President Clinical Science and Development. Rein Seensalu most recently held the position as Medical and Science Director at Novo Nordisk A/S and brings with him extensive management and clinical experience.Rein Seensalu will be responsible for the expansion of Arexis’ clinical development resources, using his international experience in clinical science and management from academia, large

Arexis enters into collaboration with CMC Biopharmaceuticals for the production of BSSL for clinical trials

Mon, Mar 07, 2005 12:00 CET

GOTHENBURG, SWEDEN – 7 March 2005 – The drug development company Arexis AB announced today that it has entered into a collaboration agreement with the Danish company CMC Biopharmaceuticals on the production of recombinant human BSSL for the upcoming cystic fibrosis and preterm infant clinical trials.The collaboration represents an important step in the preparations for the BSSL (bile salt-stimulated lipase) clinical trials in cystic fibrosis patients with fat malabsorption and preterm infants. Under the collaboration agreement, Copenhagen-based CMC Biopharmaceuticals, a contract development

Arexis’ SCCE project receives VINNOVA grant

Mon, Feb 21, 2005 14:00 CET

GOTHENBURG, SWEDEN – 21 February 2005 – The Gothenburg-based drug development company Arexis AB announced today that it has received a grant totalling SEK 6.4 million from the Swedish Agency for Innovation Systems, VINNOVAThe project will evaluate the enzyme SCCE (Stratum Corneum Chymotryptic Enzyme) as target molecule for skin disorders, in order to develop new treatments for skin disease. Already, there is strong scientific evidence that SCCE plays a role in diseases such as atopic dermatitis and Netherton’s syndrome. ”The VINNOVA grant further underlines the potential in our SCCE program

Arexis obtains orphan drug designation in the EU for novel cystic fibrosis therapy

Tue, Feb 08, 2005 10:00 CET

GOTHENBURG, SWEDEN –8 February 2005 – The Gothenburg-based drug development company Arexis AB today announced that the European Commission has granted orphan drug status for BSSL, the novel human enzyme replacement therapy for treatment of fat malabsorption in patients with cystic fibrosis. ”The orphan drug designation further underlines the positive results in our clinical trials and supports Arexis’ development towards becoming an integrated pharmaceutical company”, says Dr. Lennart Hansson, CEO at Arexis.In September 2004, Arexis presented successful results from its Phase II clinical

AREXIS PRESENTS SUCCESSFUL PHASE II RESULTS OF NOVEL THERAPY FOR CYSTIC FIBROSIS

Mon, Oct 18, 2004 10:07 CET

AREXIS PRESENTS SUCCESSFUL PHASE II RESULTS OF NOVEL THERAPY FOR CYSTIC FIBROSIS Improved lipid uptake and reduced need for pancreatic enzyme supplementation in patients with cystic fibrosis ST LOUIS, MISSOURI - 18 October 2004 - The Gothenburg-based drug development company Arexis AB presented last Friday the results of a successful Phase II clinical trial on their novel human enzyme replacement therapy for treatment of fat malabsorption in patients with cystic fibrosis. The presentation was made at the 18th Annual North American Cystic Fibrosis Conference in St Louis, Missouri, by Dr.

Arexis in Commercial Collaboration with Beiersdorf around Novel Skin Care Concept

Mon, Oct 11, 2004 10:09 CET

Arexis in Commercial Collaboration with Beiersdorf around Novel Skin Care Concept GOTHENBURG, SWEDEN - 11 October 2004 - The Gothenburg-based drug development company Arexis AB today announced a commercial agreement with the German corporation Beiersdorf - one of the leading international branded goods manufacturers - around the development of new compounds for the skin care market. This agreement is the result of an ongoing, productive R&D collaboration between the two companies. The novel concept is scheduled to hit the market once clinical studies have demonstrated its superiority.

AREXIS GETS EU FUNDING FOR A CLINICAL STUDY ON IMPROVED NUTRITION IN PRETERM INFANTS

Wed, Sep 22, 2004 12:08 CET

AREXIS GETS EU FUNDING FOR A CLINICAL STUDY ON IMPROVED NUTRITION IN PRETERM INFANTS GOTHENBURG, SWEDEN - 22 September 2004 - The Gothenburg-based drug development company Arexis AB today announced that its novel project on bile salt-stimulated lipase (BSSL), an enzyme present in human milk, has received financial support from the EU. A clinical Phase II trial will commence in 2005. The study is part of the EU´s 6th Framework initiative EARNEST, which includes integrated epidemiological, genetic, animal, consumer and economic research on improved nutrition for preterm infants and its

Arexis acquires project in lipid metabolism

Tue, Feb 17, 2004 12:00 CET

Arexis acquires project in lipid metabolism Arexis has acquired a project concerning human bile salt stimulated lipase, BSSL, from AstraZeneca. The aim of the project is to develop a new type of substitution therapy for patients suffering from pancreatic dysfunction, for example for those with cystic fibrosis, and also for preterm infants. The acquisition includes transfer of intellectual property and know how within the BSSL project previously owned by AstraZeneca to Arexis. AstraZeneca will receive milestone and royalty payments. In addition, Arexis has acquired an exclusive licence to

Arexis AB has today initiated a phase II clinical study in the area of lipid metabolism

Tue, Jul 08, 2003 15:31 CET

Arexis AB has today initiated a phase II clinical study in the area of lipid metabolism. The study will be completed before the end of this year. Further details will be released shortly. Arexis AB is a drug discovery and development company, pioneering the use of genetics in highly selected disease models to pinpoint specific genes involved in multifactorial metabolic and inflammatory diseases. Founded in 1999, Arexis is dedicated to addressing unmet medical needs and delivering improved therapies based on effective and selective new drugs. The head office is in Gothenburg. For more

Swedish drug discovery company Arexis AB raises SEK 63 million

Tue, Jul 01, 2003 12:49 CET

Swedish drug discovery company Arexis AB raises SEK 63 million Arexis AB today announced the completion of a 63 million SEK private placement in which Industrifonden as a new investor and major owner joins current owners 3i, SEB Företagsinvest and InnovationsKapital also participating in the placement. Founded in 1999, Arexis has built a competitive drug discovery and development organization with a focus on metabolic and inflammatory diseases. Arexis bases its activities on proprietary technologies elucidating genetic components of common diseases in a uniquely time and resource efficient

Patent approval for treating common skin disorders

Wed, Feb 12, 2003 10:54 CET

Patent approval for treating common skin disorders Arexis AB has received approval for a breakthrough patent application in Europe, covering a new method for treating the most common skin disorders. The patent was previously granted in North America and Australia. The treatment is based on a skin-specific enzyme, SCCE (Stratum Corneum Chymotryptic Enzyme), which affects, among others, the skin barrier function. Based on the granted patent, Arexis has started developing therapeutics for treating psoriasis and atopic dermatitis, and skin-care products aimed at individuals with dry and

Gene discovery points to new possibilities for the treatment of rheumatoid arthritis

Tue, Dec 03, 2002 10:58 CET

Gene discovery points to new possibilities for the treatment of rheumatoid arthritis Swedish researchers at the University of Lund and Arexis AB have identified a gene that plays a key role in arthritis development. This breakthrough, published in Nature Genetics, will be of crucial importance for the development of new therapies against rheumatoid arthritis (RA) as well as other severe inflammatory diseases such as multiple sclerosis. RA is a chronic and debilitating autoimmune condition that results from a complex interplay between several genes and environmental factors. This complexity

Arexis announces completion of 48 million SEK private placement.

Wed, May 30, 2001 13:06 CET

Arexis announces completion of 48 million SEK private placement. Arexis AB today announces the completion of a 48 million SEK private placement. 3i Group plc and SEB Företagsinvest have each invested 20 million SEK while the existing shareholders InnovationsKapital and investors affiliated to the Beijer Group each have invested 4 million SEK. In addition, the Swedish Industrial Development Fund recently provided 5 million SEK as a convertible loan. The proceeds will be used to expand the organization and build an industrial platform for the company's research and development programme.

Share